CNCR vs. JDOC

Last updated Jun 24, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and JDOC (Jpmorgan Healthcare Leaders ETF) are both Health & Biotech Equities funds. CNCR is passively managed, while JDOC is actively managed. CNCR charges 0.79%/yr vs 0.65%/yr for JDOC.

Performance

CNCR vs. JDOC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Jpmorgan Healthcare Leaders ETF (JDOC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

JDOC

• 1D: 1.11%
• 1M: 2.00%
• YTD: -0.08%
• 6M: -0.49%
• 1Y: 17.29%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. JDOC - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
JDOC Jpmorgan Healthcare Leaders ETF	-0.08%

CNCR vs. JDOC - Sectors Allocation Comparison

Sectors	CNCR	JDOC
Healthcare	96.6%	100.0%
Financial Services	3.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. JDOC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

JDOC

JDOC Risk / Return Rank: 36
JDOC Sharpe Ratio Rank: 36
JDOC Sortino Ratio Rank: 39
JDOC Omega Ratio Rank: 34
JDOC Calmar Ratio Rank: 38
JDOC Martin Ratio Rank: 33

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. JDOC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Jpmorgan Healthcare Leaders ETF (JDOC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CNCR	JDOC	Difference
Sharpe ratio: Return per unit of total volatility	—	1.21	—
Sortino ratio: Return per unit of downside risk	—	1.92	—
Omega ratio: Gain probability vs. loss probability	—	1.22	—
Calmar ratio: Return relative to maximum drawdown	—	1.79	—
Martin ratio: Return relative to average drawdown	—	4.54	—

Drawdowns

CNCR vs. JDOC - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum JDOC drawdown of -20.87%. Use the drawdown chart below to compare losses from any high point for CNCR and JDOC.

Drawdown Indicators

	CNCR	JDOC	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-20.87%	+20.87%
Max Drawdown (1Y) Largest decline over 1 year	—	-9.68%	—
Current Drawdown Current decline from peak	0.00%	-3.20%	+3.20%
Average Drawdown Average peak-to-trough decline	0.00%	-6.93%	+6.93%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.81%	—

Volatility

Volatility by Period

	CNCR	JDOC	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	5.26%	—
Volatility (6M) Calculated over the trailing 6-month period	—	10.56%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	14.35%	-14.35%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	14.52%	-14.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	14.52%	-14.52%

CNCR vs. JDOC - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than JDOC's 0.65% expense ratio.

Dividends

CNCR vs. JDOC - Dividend Comparison

CNCR has not paid dividends to shareholders, while JDOC's dividend yield for the trailing twelve months is around 0.89%.

Position	TTM	2025	2024	2023
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%
JDOC Jpmorgan Healthcare Leaders ETF	0.89%	0.89%	5.57%	0.15%

Frequently Asked Questions

Which ETF is better, CNCR or JDOC?

On fees, JDOC is cheaper at 0.65% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or JDOC?

JDOC is cheaper with a 0.65% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or JDOC?

JDOC has the higher dividend yield at 0.89%, compared with 0.00% for CNCR.

What is the main difference between CNCR and JDOC?

They also come from different issuers: Exchange Traded Concepts and JPMorgan. Their fees differ too: 0.79% for CNCR and 0.65% for JDOC.